Form 4: Sotera Health Co Executive Michael Rutz Reports Stock Transactions

Michael Rutz, President of Sterigenics (Sotera Health Co), reports acquisition and disposal of shares and stock options, including sales in a public secondary offering.

Summary

• Michael Rutz, President of Sterigenics, reported several transactions involving Sotera Health Co [SHC] common stock and stock options.
• On March 2, 2024, shares were withheld to cover tax obligations related to vesting Restricted Stock Units (RSUs) from grants in 2022 (2,438 shares at $14.56) and 2023 (3,063 shares at $14.56).
• On March 4, 2024, Rutz was granted 34,270 RSUs and sold 83,109 shares at $14.3075 as part of an underwritten public secondary offering.
• Rutz also acquired 68,063 stock options on March 4, 2024, exercisable at $14.59, expiring on March 4, 2034.
• Following these transactions, Rutz directly owns 544,409 shares of common stock (including vested and unvested RSUs) and holds various stock options granted between 2020 and 2024.
• The sales were part of a larger public secondary offering by Sotera Health Co.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the sale of shares could be seen as slightly negative, it was part of a planned secondary offering. The granting of RSUs and stock options is a positive sign.

Positives

• The granting of RSUs and stock options to the reporting person could be seen as an incentive to align management's interests with those of shareholders.

Negatives

• The sale of 83,109 shares by the reporting person could be interpreted negatively by the market, although it was part of a larger public secondary offering.

Risks

• The vesting of RSUs and stock options is contingent upon continued service, which introduces a risk of potential loss of these incentives if the reporting person leaves the company.
• Market conditions could impact the value of the shares and stock options held by the reporting person.

Future Outlook

The RSUs granted on March 4, 2024, vest annually in three equal installments commencing March 2, 2025. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025.

Industry Context

Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's future prospects. Secondary offerings are a typical way for companies and major shareholders to raise capital.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the healthcare industry, used to incentivize executives at companies like Steris, Varex Imaging, and Accuray.
• The vesting schedules described are typical, with three-year vesting periods being common.
• Secondary offerings are frequently used by companies in the sector to provide liquidity for early investors or to raise capital for specific initiatives.

Stakeholder Impact

• Shareholders may be impacted by the secondary offering, potentially diluting existing ownership.
• Employees may be impacted by the vesting of RSUs and stock options, aligning their interests with the company's performance.

Next Steps

• Vesting of RSUs granted on March 4, 2024, will commence on March 2, 2025.
• Unvested common stock will vest on a daily basis, pro rata through May 13, 2025.

Key Dates